Aficamten is a cardiac myosin inhibitor for the treatment of obstructive hypertrophic cardiomyopathy.
Tradename Myqorzo.
It is a selective cardiac myosin inhibitor that reduces the force of heart muscle contraction.
It is specifically for patients with obstructive hypertrophic cardiomyopathy (OHCM)
It blocks cardiac myosin, reducing the excessive contractility that characterizes HCM.
It reduces myocardial hypercontractility by decreasing the number of active actin-myosin cross bridges within the sarcomere.
It helps decrease left ventricular outflow tract obstruction, and improves symptoms like shortness of breath, chest pain, and exercise intolerance
Traditional treatments focus on symptom management rather than addressing the underlying excessive heart muscle contraction.
Among patients with symptomatic obstructive HCM, aficamten monotherapy was superior metoprolol monotherapy and improving peak oxygen uptake and hemodynamics and decreasing symptoms.